[go: up one dir, main page]

WO2025080877A3 - Therapeutic peptides - Google Patents

Therapeutic peptides Download PDF

Info

Publication number
WO2025080877A3
WO2025080877A3 PCT/US2024/050828 US2024050828W WO2025080877A3 WO 2025080877 A3 WO2025080877 A3 WO 2025080877A3 US 2024050828 W US2024050828 W US 2024050828W WO 2025080877 A3 WO2025080877 A3 WO 2025080877A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid ceramidase
peptide
therapeutic peptides
inhibits
therapeutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/050828
Other languages
French (fr)
Other versions
WO2025080877A2 (en
Inventor
Natasha SHTRAIZENT
Lina FREAGE-KAHN
Saliha NAFIL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frezent Biological Solutions Inc
Original Assignee
Frezent Biological Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frezent Biological Solutions Inc filed Critical Frezent Biological Solutions Inc
Publication of WO2025080877A2 publication Critical patent/WO2025080877A2/en
Publication of WO2025080877A3 publication Critical patent/WO2025080877A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides compositions and methods directed to a peptide that inhibits acid ceramidase and treatment of diseases or disorders associated with acid ceramidase. A method for treating a disease or disorder associated with acid ceramidase (e.g., cancer) may involve administering a therapeutically-effective amount of a peptide that inhibits acid ceramidase.
PCT/US2024/050828 2023-10-10 2024-10-10 Therapeutic peptides Pending WO2025080877A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363589058P 2023-10-10 2023-10-10
US63/589,058 2023-10-10

Publications (2)

Publication Number Publication Date
WO2025080877A2 WO2025080877A2 (en) 2025-04-17
WO2025080877A3 true WO2025080877A3 (en) 2025-06-05

Family

ID=95395204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/050828 Pending WO2025080877A2 (en) 2023-10-10 2024-10-10 Therapeutic peptides

Country Status (1)

Country Link
WO (1) WO2025080877A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080877A2 (en) * 2023-10-10 2025-04-17 Frezent Biological Solutions, Inc. Therapeutic peptides

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051415A2 (en) * 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
US20190359662A1 (en) * 2016-06-21 2019-11-28 The University Of Queensland Spider venom peptides and methods of use for modulating sodium channels
US20220119440A1 (en) * 2019-07-02 2022-04-21 AGC Inc. Peptide and method for manufacturing same
US20230159659A1 (en) * 2018-07-27 2023-05-25 Massachusetts Eye And Ear Infirmary Inhibition of cystatins for the treatment of chronic rhinosinusitis
WO2025080877A2 (en) * 2023-10-10 2025-04-17 Frezent Biological Solutions, Inc. Therapeutic peptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051415A2 (en) * 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
US20190359662A1 (en) * 2016-06-21 2019-11-28 The University Of Queensland Spider venom peptides and methods of use for modulating sodium channels
US20230159659A1 (en) * 2018-07-27 2023-05-25 Massachusetts Eye And Ear Infirmary Inhibition of cystatins for the treatment of chronic rhinosinusitis
US20220119440A1 (en) * 2019-07-02 2022-04-21 AGC Inc. Peptide and method for manufacturing same
WO2025080877A2 (en) * 2023-10-10 2025-04-17 Frezent Biological Solutions, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
WO2025080877A2 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
CN1874784B (en) Treatment of chronic facial pain and headache associated with sinusitis with botulinum toxin
WO2020205473A8 (en) Compositions and methods for the treatment of kras associated diseases or disorders
NZ254404A (en) Substituted 1,4-dihydroquinoxaline-2,3-diones and pharmaceutical compositions thereof
CY1105199T1 (en) THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF MUCUS DISCHARGE
JP6190368B2 (en) Combination therapy using immunoglobulins and C1-inhibitors
JP2007528352A5 (en) Treatment of chronic facial pain and headache associated with sinusitis with botulinum toxin
US9975931B2 (en) Use of an immunomodulatory protein from Ganoderma in promoting neurite outgrowth
WO2025080877A3 (en) Therapeutic peptides
BR112021017203A2 (en) Leucine, acetyl leucine and related analogues for the treatment of diseases
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MX2023014658A (en) Method for treating chronic obstructive pulmonary disease with an st2 antagonist.
CN1917898B (en) Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung infections
MX2024000049A (en) Bruton's tyrosine kinase and mutant degrader, composition and application thereof.
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
MX2023002350A (en) Compositions and methods for improving neurological diseases and disorders.
WO2024158838A3 (en) Methods and compositions for combination therapy
MX2022006052A (en) Caspase 6 inhibitors and uses thereof.
WO2007038428A3 (en) Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds
EP0885013B1 (en) Use of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses for the preparation of medicaments
WO2024112527A3 (en) Methods for the treatment of thyroid eye disease
JP2015147764A5 (en)
CN101180044B (en) EGF/GHRP-6 Combination for Central Nervous System Nerve Regeneration After Autoimmune Injury
WO2025122753A3 (en) Compositions and methods for the treatment of niemann-pick disease
WO2024137991A3 (en) Engineered guide rnas and polynucleotides
WO2024073328A3 (en) Vanoxerine for use in the treatment of brain cancer, breast cancer, pancreatic cancer and lung cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24878031

Country of ref document: EP

Kind code of ref document: A2